Reports state that Pfizer vaccine reduces symptomatic Covid Cases
Pfizer-BioNTech’s COVID-19 vaccine appears to reduce symptomatic coronavirus infections by more than 90 per cent in the real world, according to researchers.The preliminary findings published on Monday suggest that the vaccine remains remarkably effective in a mass vaccination campaign outside the carefully controlled conditions of a clinical trial.
Japan’s Health Ministry said on Sunday it has officially approved Pfizer Inc’s Covid-19 vaccine, the first such approval in the country as it steps up efforts to tame a third wave of infections in the run-up to the Summer Olympic Games. The move had been widely expected after a government panel recommended approval on Friday, at which point Health Minister Norihisa Tamura said Japan would give its final approval as soon as possible.
The first 60,000 doses of the Pfizer/BioNTech coronavirus vaccine arrived in New Zealand on Monday, Prime Minister Jacinda Ardern said. The news comes as New Zealand put its most populous city of Auckland on three-day Level 3 lockdown after detecting three Covid-19 community cases, which were the more transmissible UK virus variant. The rest of the country moved to Level 2 lockdown for the same period. The restrictions will be reviewed on a 24-hour basis.
Australia is contracted to receive 20 million Pfizer doses and to receive or manufacture at home 53.8 million AstraZeneca doses. Australia will begin vaccinating its population against COVID-19 next week after its first shipment of Pfizer vaccine was delivered on Monday.